ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Virginia » Rheumatology

Top Rheumatology Prescribers in Virginia

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
MOHSEN GHAFOURI MD

Rheumatology

2,408

$303K

487
405 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

4%
patients receiving schedule three controlled substances

Avg: 9%

7%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

36%
prescriptions for brand name drugs

Avg: 24%

$126
Average prescription price

Avg: $132

ADEGBENGA BANKOLE M.D.

Rheumatology

2,178

$233K

308
203 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 24%

$107
Average prescription price

Avg: $132

JOHN PENDLETON M.D.

Rheumatology

2,131

$400K

215
139 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

14%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 24%

$188
Average prescription price

Avg: $132

MARY HAGERTY MD

Rheumatology

2,083

$361K

170
120 are 65+

11%
patients receiving schedule two controlled substances

Avg: 4%

24%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

26%
prescriptions for brand name drugs

Avg: 24%

$173
Average prescription price

Avg: $132

MARIA DARLAND M.D.

Rheumatology

2,015

$154K

154
110 are 65+

8%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 24%

$77
Average prescription price

Avg: $132

CHRISTOPHER HAKIM MD

Rheumatology

1,986

$312K

279
208 are 65+

10%
patients receiving schedule two controlled substances

Avg: 4%

13%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

26%
prescriptions for brand name drugs

Avg: 24%

$157
Average prescription price

Avg: $132

PHONG NGUYEN MD

Rheumatology

1,965

$658K

241
197 are 65+

6%
patients receiving schedule two controlled substances

Avg: 4%

7%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

35%
prescriptions for brand name drugs

Avg: 24%

$335
Average prescription price

Avg: $132

JOHN MANSOOR M.D.

Rheumatology

1,956

$308K

220
168 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

19%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 24%

$158
Average prescription price

Avg: $132

CLAUDE ABUJRAB-SABA M.D.

Rheumatology

1,857

$298K

198
143 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

19%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

27%
prescriptions for brand name drugs

Avg: 24%

$161
Average prescription price

Avg: $132

KATHLEEN PRICE MD

Rheumatology

1,855

$459K

142
109 are 65+

17%
patients receiving schedule two controlled substances

Avg: 4%

13%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

29%
prescriptions for brand name drugs

Avg: 24%

$247
Average prescription price

Avg: $132

AVNIT AHUJA MD

Rheumatology

1,763

$125K

171
113 are 65+

11%
patients receiving schedule two controlled substances

Avg: 4%

11%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 24%

$71
Average prescription price

Avg: $132

TAMMY SPRING M.D.

Rheumatology

1,741

$196K

265
204 are 65+

5%
patients receiving schedule two controlled substances

Avg: 4%

5%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 24%

$113
Average prescription price

Avg: $132

MIHAIL MOROIANU M.D.

Rheumatology

1,705

$106K

258
195 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

10%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 24%

$62
Average prescription price

Avg: $132

ALBERT LEE M.D.

Rheumatology

1,673

$193K

217
150 are 65+

8%
patients receiving schedule two controlled substances

Avg: 4%

8%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

27%
prescriptions for brand name drugs

Avg: 24%

$115
Average prescription price

Avg: $132

ANNE BACON MD

Rheumatology

1,618

$156K

142
120 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 24%

$97
Average prescription price

Avg: $132

CATHERINE DANIEL M.D.

Rheumatology

1,605

$346K

198
143 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

7%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

25%
prescriptions for brand name drugs

Avg: 24%

$215
Average prescription price

Avg: $132

JENNIFER ODUTOLA M.D.

Rheumatology

1,601

$218K

149
97 are 65+

10%
patients receiving schedule two controlled substances

Avg: 4%

25%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

26%
prescriptions for brand name drugs

Avg: 24%

$136
Average prescription price

Avg: $132

SARAH CLARKSON M.D.

Rheumatology

1,570

$306K

212
155 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 24%

$195
Average prescription price

Avg: $132

ANDRONIKI BILI M.D.

Rheumatology

1,559

$343K

202
142 are 65+

7%
patients receiving schedule two controlled substances

Avg: 4%

12%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 24%

$220
Average prescription price

Avg: $132

ANDREW MILLER DO

Rheumatology

1,555

$142K

246
178 are 65+

8%
patients receiving schedule two controlled substances

Avg: 4%

24%
patients receiving schedule three controlled substances

Avg: 9%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 24%

$91
Average prescription price

Avg: $132

JULIANNE ORLOWSKI D.O.

Rheumatology

1,532

$208K

243
176 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

23%
patients receiving schedule three controlled substances

Avg: 9%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 24%

$136
Average prescription price

Avg: $132

JOHN MELTON M.D.

Rheumatology

1,531

$120K

146
116 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

14%
patients receiving schedule three controlled substances

Avg: 9%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 24%

$79
Average prescription price

Avg: $132

ROSALIA LOMEO M.D.

Rheumatology

1,524

$226K

101
56 are 65+

25%
patients receiving schedule two controlled substances

Avg: 4%

27%
patients receiving schedule three controlled substances

Avg: 9%

7%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 24%

$148
Average prescription price

Avg: $132

WILLIAM REED M.D.

Rheumatology

1,485

$250K

173
106 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

21%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

27%
prescriptions for brand name drugs

Avg: 24%

$168
Average prescription price

Avg: $132

KEITH FRICK M.D.

Rheumatology

1,483

$249K

229
188 are 65+

0%
patients receiving schedule two controlled substances

Avg: 4%

0%
patients receiving schedule three controlled substances

Avg: 9%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 24%

$168
Average prescription price

Avg: $132

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank